alexa Bioanalytical Strategy For Biosimilars: Recommended Steps For Establishment Of Comparability
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference and Exhibition on Biowaivers, Biologics & Biosimilars
October 27-29, 2014 Hyderabad International Convention Centre, Hyderabad, India

Aparna Kasinath
ScientificTracks Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X.S1.013
Bioanalytical comparability is an important step in establishing biosimilarity between a biosimilar and its reference therapeutic. Results from bioanalytical analyses determine the final efficacy of a biosimilar drug compared to its reference therapeutic; in a head to head trial. Ligand binding assays are one of the most popular and routinely used analytical techniques for the bioanalysis of biosimilars. For dependable results, drug specific ligand binding assay development and fit for purpose validation should follow unique strategies for comparison of any two specific drugs. Owing to the complexity in the structure of biosimilars, adequate study of the two drugs in the development and validation phasesshould be done before designing sample analysis studies. Appropriate statistical tools should be employed in interpreting assay results to ensure that differences, if any, are called out on time. In this discussion, recommendation on appropriate and systematic strategies for comparability of Biosimilars using ligand binding assays will be made based on the author?s experience and current regulatory expectations.
Aparna Kasinath is currently the Head and Test Facility Management of the Regulated Bioanalytical Laboratory at Clinigene International Limited. She has more than 12 years of assay experience which includes more than 7 years of experience in Immunoassay Development/Transfer, Validation and Sample analysis in support of PK and Immunogenicity studies for novel biologics and biosimilars. She has a PhD from Sardar Patel University, Gujarat, India and was selected as a UNESCO fellow to the Czech Academy of Sciences, Prague- as a part of her PhD program. She is an active member of various Bioanalytical Groups and works to not only to synchronize Indian Bioanalytical Practices with Global Regulatory Requirements, but also strives to bring out the Indian Bioanalytical Perspective on to a Global Platform for effective Harmonization.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version